So I was thinking that any response to the attacks on Saudi Arabia would happen sooner rather than later but I am no longer convinced that remains the case. Clearly Saudi Arabia was taken by surprise and so it needs to tighten its defenses before escalating the situation (if they choose to escalate). A kinetic […]
It is looking like a macro week, although this could resolve itself fairly quickly. The attacks on the ARAMCO production facility is likely to have long term effects on oil but whether or not this leads to a broader conflict should be decided in a couple of days. Obviously there will be some response but […]
San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock continued to climb, TPTX quickly filed for a secondary on September 3rd, adding another $200M to its cash hoard. The company is now very well […]
(Sorry for the delay. The site worked but we had an issue with posting new articles. It is now fixed) The resilience of the sector is a little surprising and could pay off. It had been looking like a breakdown candidate but never followed through on that potential. Now it is looking like a breakout […]
Surprise. The sector is weak. I am a little surprised that we are not see a faster sell off as clearly there is no momentum and we have broken support. This really seems like a nice and orderly sell off and this is not necessarily good. The selling does not end when there is no […]
We have some interesting news to start the week and of course it leads to a flat sector with the broader market green. It seems like the sector is underperforming and again I think that is odd given how well the earnings came through last quarter. Perhaps we are close enough to the election that […]
I have class about to begin but I want to put out a quick note on the news. GBT announced that the FDA has accepted the NDA for voxelotor with a PDUFA date of February 26th, 2020. The stock is moving on the news. I do not see the filing as the real news as […]
I have been following Arqule off and on for quite some time. The company has been reborn after so many lost years pursuing its failed MET inhibitor ARQ 197. Hopes are high for lead asset ARQ 531, a competitive inhibitor of BTK. Arqule also has a pipeline of 2 AKT inhibitors and an out-licensed FGFR […]
The sector is in an odd spot. It seems to be right under a major support but has not quite broken down. I suspect we cannot remain at these levels for much longer, although we twice went down to the $78 level on the XBI. Given that the $78 twice was tested and held that […]
We remain in the summer doldrums but more than that we are stuck in the macro issues. Between a potential recession to the China trade war, it is virtually impossible to get through a week without something whipping the sector and market. Today we might actually be getting to a point where China starts to […]
I will keep this short and sweet as there is little news to talk about. On the positive side, the sector seems to be doing better and while I would not call it a false breakdown yet, the possibility remains. Clearly we need a continuation rally but we got exactly what we needed yesterday. Today […]
I think today is the day. The sector is at a very precarious positon. It has dropped below what was support but I still think it has a chance to make that into a false breakdown. A rally above that previous support level and one that strengthens as the day continues is crucial. The worst […]
Aug 27, 2019 by Jason Chew Zogenix announced yesterday that it is acquiring privately held Modis Therapeutics. It gains access to the late stage substrate enhancement therapy, MT1621, for the treatment of Thymidine Kinase 2 deficiency (TK2d). Zogenix is paying $250M upfront, consisting of $175M cash and $75M stock. Modis may also receive milestones of […]
Market starts the week higher but I do not trust it as there is the old saying that markets never bottom on Fridays. To be fair futures were down a lot and have rallied before the market opened but I remain suspicious of the green open. The ideal scenario for a robust turnaround would be […]
Aug 23, by Jason Chew Arvinas is one of the newer names I’ve been covering. The company is developing a new class of drugs with a new modality known as Targeted Protein Degraders, coining the technology PROTAC (Proteolysis Targeting Chimera). PROTACs work in a completely different way from current small molecule drugs. Most of today’s […]
So the sector feels a lot worse than the chart indicates. We are right around support at $80 and that seems to have been holding. We are approaching, however, a decision point. We can break below what is support for a leg down or break out of the downward trending making that look like a […]
Broadly speaking the sector and market are doing well. Sentiment has been pretty negative and there were some macro concerns. This seems to be easing a bit, so a rally might be in the offing but how many times have we been burning at the start of rallies with some new macro concern jumping to […]
So I do not want to spend a lot of time on macro or the sector as it is the same but we do have some really important news to discuss that is both stock and sector important. 1. SRPT received a CRL. This was a surprise both to me and the company. According to […]
Aug 19, 2019 by Jason Chew Zogenix ran into some unwelcome surprise this April when FDA kicked back its ZX008 (Fintepla) NDA with a Refuse to File letter. The two deficiencies cited were the lack of a non-clinical toxicology report and submission of an incorrect clinical dataset. The request for additional toxicology studies was unexpected; management believed […]
